# EPR Tumor Oximetry With CE India Ink

> **NCT03321903** · — · TERMINATED · sponsor: **Philip Schaner** · enrollment: 3 (actual)

## Conditions studied

- Neoplasms, Malignant
- Breast Neoplasm
- Carcinoma, Basal Cell
- Carcinoma, Squamous Cell
- Melanoma
- Skin Neoplasm
- Head and Neck Neoplasms

## Interventions

- **DEVICE:** Carlo Erba Ink Injection
- **OTHER:** EPR Oximetry Measurement

## Key facts

- **NCT ID:** NCT03321903
- **Lead sponsor:** Philip Schaner
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-30
- **Primary completion:** 2019-10-27
- **Final completion:** 2019-10-27
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** The research team is exploring device optimization
- **Last updated:** 2019-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03321903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03321903, "EPR Tumor Oximetry With CE India Ink". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03321903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*